Keisuke Umemura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Keisuke Umemura has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Tomohiro Terada
Department of Clinical Pharmacology and Therapeutics Kyoto University Hospital Kyoto Japan
9 shared publications - Yoshiki Katada
Department of Clinical Pharmacology and Therapeutics Kyoto University Hospital Kyoto Japan
9 shared publications - Miki Nagao
Department of Clinical Laboratory Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
7 shared publications - Shunsaku Nakagawa
Department of Clinical Pharmacology and Therapeutics Kyoto University Hospital Kyoto Japan
7 shared publications - Yurie Katsube
Department of Clinical Pharmacology and Therapeutics Kyoto University Hospital Kyoto Japan
6 shared publications - Daiki Hira
Department of Clinical Pharmacology and Therapeutics Kyoto University Hospital Kyoto Japan
5 shared publications
Latest Publications
- Open Access
- 18 August 2026
- Published by Elsevier in Transplantation Proceedings
- Vol. 58 (8) , 1632-1644
Association Between Perioperative Use of Fourth- Versus First-Generation Cephalosporins and Early Bacterial Infections, Chronic Lung Allograft Dysfunction-Free Survival, and 1- and 5-Year Survival: A Cohort Study
- 18 August 2026
- Published by Elsevier in Transplantation Proceedings
- Vol. 58 (8) , 1632-1644
Open AccessAssociation Between Perioperative Use of Fourth- Versus First-Generation Cephalosporins and Early Bacterial Infections, Chronic Lung Allograft Dysfunction-Free Survival, and 1- and 5-Year Survival: A Cohort Study
- 6 May 2026
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 32 (6) , 102986
Valganciclovir therapeutic drug monitoring-guided dosing for cytomegalovirus prophylaxis in lung transplant patients
- 6 May 2026
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 32 (6) , 102986
Valganciclovir therapeutic drug monitoring-guided dosing for cytomegalovirus prophylaxis in lung transplant patients
- Open Access
- 18 August 2025
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (8) , e70317
CYP2C19‐Guided Voriconazole Therapy: A Precision Medicine Approach to Mitigate Adverse Effects in Japanese Patients
Voriconazole (VRCZ) is a triazole antifungal agent with a broad antifungal spectrum. It is metabolized by hepatic cytochrome P450 (CYP) isozyme CYP2C19, whose genetic polymorphism causes significant variability in drug efficacy and safety. Poor metabolizer alleles of CYP2C19 are more common in Asian populations, increasing the risk of supratherapeutic VRCZ levels. We have developed a novel nomogram based on CYP2C19 genetic polymorphisms. This study aimed to evaluate whether CYP2C19 genotype‐guided VRCZ therapy reduces toxicity in Japanese patients. This retrospective study included 64 patients (genotype‐guided group, n = 26; comparison group, n = 38). The primary outcome was defined as the composite incidence of adverse events commonly observed with VRCZ, represented by the combined occurrence of grade ≥ 2 hepatotoxicity and visual symptoms. Secondary outcomes included the proportion of patients maintaining VRCZ trough concentrations within the therapeutic range (1–4 μg/mL) and the treatment response at 28 days. The composite incidence of adverse events was significantly lower in the genotype‐guided group than in the comparison group (p = 0.003). VRCZ discontinuation due to adverse events occurred in nine patients (23.7%) in the comparison group and one (3.8%) in the genotype‐guided group (p = 0.039). More patients in the genotype‐guided group were achieved through concentrations within the therapeutic range at the initial sampling point. However, treatment response rates did not differ significantly between the groups. VRCZ administration based on CYP2C19 genotyping improved therapeutic trough levels management and reduced adverse effects while maintaining therapeutic efficacy. These findings highlight the importance of CYP2C19 genotyping for VRCZ treatment in Japanese patients.
- 18 August 2025
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (8) , e70317
Open AccessCYP2C19‐Guided Voriconazole Therapy: A Precision Medicine Approach to Mitigate Adverse Effects in Japanese Patients
Voriconazole (VRCZ) is a triazole antifungal agent with a broad antifungal spectrum. It is metabolized by hepatic cytochrome P450 (CYP) isozyme CYP2C19, whose genetic polymorphism causes significant variability in drug efficacy and safety. Poor metabolizer alleles of CYP2C19 are more common in Asian populations, increasing the risk of supratherapeutic VRCZ levels. We have developed a novel nomogram based on CYP2C19 genetic polymorphisms. This study aimed to evaluate whether CYP2C19 genotype‐guided VRCZ therapy reduces toxicity in Japanese patients. This retrospective study included 64 patients (genotype‐guided group, n = 26; comparison group, n = 38). The primary outcome was defined as the composite incidence of adverse events commonly observed with VRCZ, represented by the combined occurrence of grade ≥ 2 hepatotoxicity and visual symptoms. Secondary outcomes included the proportion of patients maintaining VRCZ trough concentrations within the therapeutic range (1–4 μg/mL) and the treatment response at 28 days. The composite incidence of adverse events was significantly lower in the genotype‐guided group than in the comparison group (p = 0.003). VRCZ discontinuation due to adverse events occurred in nine patients (23.7%) in the comparison group and one (3.8%) in the genotype‐guided group (p = 0.039). More patients in the genotype‐guided group were achieved through concentrations within the therapeutic range at the initial sampling point. However, treatment response rates did not differ significantly between the groups. VRCZ administration based on CYP2C19 genotyping improved therapeutic trough levels management and reduced adverse effects while maintaining therapeutic efficacy. These findings highlight the importance of CYP2C19 genotyping for VRCZ treatment in Japanese patients.
- 21 July 2025
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 48 (1) , 134-139
Efficient Penetration of Terbinafine into Brain Abscesses in a Lung Transplant Recipient with Scedosporiosis: A Short Communication
Background: Scedosporium spp. typically infect the lungs and can disseminate to various tissues, including the central nervous system (CNS). Voriconazole and terbinafine are both used to treat scedosporiosis. While voriconazole has been reported to have good CNS permeability, the permeability of terbinafine in humans remains unclear. Methods: The authors describe a case of Scedosporium apiospermum infection with brain abscesses in a lung transplant recipient treated with voriconazole and terbinafine. Drug concentrations were measured in the biopsied brain abscess, the surrounding normal cerebrum, serum, and cerebrospinal fluid (CSF). Brain-to-serum and CSF-to-serum partition coefficients for each drug were calculated based on serum concentrations estimated at the time of abscess biopsy and lumbar puncture using population pharmacokinetic models. Results: Trough serum concentrations of voriconazole and terbinafine were 6.28 mcg/mL and 0.41 mcg/mL, respectively. Seven hours after administration, the concentrations in cerebrum were 5.65 mcg/mL and 0.85 mcg/mL, respectively, and those in brain abscess were 4.05 mcg/mL and 1.06 mcg/mL, respectively. The estimated brain-to-serum partition coefficients were 0.730 for voriconazole and 0.553 for terbinafine, indicating substantial penetration of both drugs into the infected tissue. The brain abscess size decreased in this case, suggesting a therapeutic antifungal effect of these agents. However, the measured CSF concentrations at 5 hours postdose were 2.69 mcg/mL for voriconazole and −4 for terbinafine, indicating poor CSF permeability of terbinafine. Conclusions: These findings suggest that terbinafine has the potential to treat fungal infections within the brain, but may be less effective for CSF infections. Further studies are warranted to clarify incorporation of these agents into CNS infection treatment strategies.
- 21 July 2025
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 48 (1) , 134-139
Efficient Penetration of Terbinafine into Brain Abscesses in a Lung Transplant Recipient with Scedosporiosis: A Short Communication
Background: Scedosporium spp. typically infect the lungs and can disseminate to various tissues, including the central nervous system (CNS). Voriconazole and terbinafine are both used to treat scedosporiosis. While voriconazole has been reported to have good CNS permeability, the permeability of terbinafine in humans remains unclear. Methods: The authors describe a case of Scedosporium apiospermum infection with brain abscesses in a lung transplant recipient treated with voriconazole and terbinafine. Drug concentrations were measured in the biopsied brain abscess, the surrounding normal cerebrum, serum, and cerebrospinal fluid (CSF). Brain-to-serum and CSF-to-serum partition coefficients for each drug were calculated based on serum concentrations estimated at the time of abscess biopsy and lumbar puncture using population pharmacokinetic models. Results: Trough serum concentrations of voriconazole and terbinafine were 6.28 mcg/mL and 0.41 mcg/mL, respectively. Seven hours after administration, the concentrations in cerebrum were 5.65 mcg/mL and 0.85 mcg/mL, respectively, and those in brain abscess were 4.05 mcg/mL and 1.06 mcg/mL, respectively. The estimated brain-to-serum partition coefficients were 0.730 for voriconazole and 0.553 for terbinafine, indicating substantial penetration of both drugs into the infected tissue. The brain abscess size decreased in this case, suggesting a therapeutic antifungal effect of these agents. However, the measured CSF concentrations at 5 hours postdose were 2.69 mcg/mL for voriconazole and −4 for terbinafine, indicating poor CSF permeability of terbinafine. Conclusions: These findings suggest that terbinafine has the potential to treat fungal infections within the brain, but may be less effective for CSF infections. Further studies are warranted to clarify incorporation of these agents into CNS infection treatment strategies.
- 25 March 2025
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 31 (4) , 102686
Optimizing cytomegalovirus treatment through therapeutic drug monitoring in a ganciclovir-unresponsive lung transplant recipient
- 25 March 2025
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 31 (4) , 102686
Optimizing cytomegalovirus treatment through therapeutic drug monitoring in a ganciclovir-unresponsive lung transplant recipient
- 20 May 2024
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 30 (12) , 1222-1227
Investigation of severe acute respiratory syndrome coronavirus 2 infection status in solid organ transplant recipients treated with tixagevimab/cilgavimab
- 20 May 2024
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 30 (12) , 1222-1227
Investigation of severe acute respiratory syndrome coronavirus 2 infection status in solid organ transplant recipients treated with tixagevimab/cilgavimab
- Open Access
- 23 February 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (6) , 944-953
Fibrotic progression from acute cellular rejection is dependent on secondary lymphoid organs in a mouse model of chronic lung allograft dysfunction
- 23 February 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (6) , 944-953
Open AccessFibrotic progression from acute cellular rejection is dependent on secondary lymphoid organs in a mouse model of chronic lung allograft dysfunction
- 12 February 2024
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 30 (8) , 741-745
Comparison of the safety and cost-effectiveness of nebulized liposomal amphotericin B and amphotericin B deoxycholate for antifungal prophylaxis after lung transplantation
- 12 February 2024
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 30 (8) , 741-745
Comparison of the safety and cost-effectiveness of nebulized liposomal amphotericin B and amphotericin B deoxycholate for antifungal prophylaxis after lung transplantation